{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T03:14:44Z","timestamp":1783480484266,"version":"3.55.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T00:00:00Z","timestamp":1635811200000},"content-version":"vor","delay-in-days":2007,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Ronald and Rita McAulay Foundation"},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C5047\/A13232"],"award-info":[{"award-number":["C5047\/A13232"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Society for Medical Oncology Clinical Research Fellowship"},{"DOI":"10.13039\/100006293","name":"American Society of Clinical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006293","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cancer Foundation"},{"name":"Genetic Associations and Mechanisms in Oncology"},{"name":"NIH ELLIPSE","award":["U19CA148537"],"award-info":[{"award-number":["U19CA148537"]}]},{"name":"Cancer Research U.K. Senior Cancer Research Fellow","award":["C12292\/A11174"],"award-info":[{"award-number":["C12292\/A11174"]}]},{"DOI":"10.13039\/501100000027","name":"Institute of Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000027","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Royal Marsden National Health Service"},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Biomedical Research Centre"},{"DOI":"10.13039\/501100000027","name":"Institute of Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012139","name":"Royal Marsden NHS Foundation Trust","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012139","id-type":"DOI","asserted-by":"crossref"}]},{"name":"iCOGS infrastructure came from the European Community\u2019s Seventh Framework Programme","award":["223175"],"award-info":[{"award-number":["223175"]}]},{"name":"iCOGS infrastructure came from the European Community\u2019s Seventh Framework Programme","award":["HEALTH-F2-2009-223175"],"award-info":[{"award-number":["HEALTH-F2-2009-223175"]}]},{"name":"Cancer Research U.K.","award":["C1287\/A10118"],"award-info":[{"award-number":["C1287\/A10118"]}]},{"name":"Cancer Research U.K.","award":["C1287\/A 10710"],"award-info":[{"award-number":["C1287\/A 10710"]}]},{"name":"Cancer Research U.K.","award":["C12292\/A11174"],"award-info":[{"award-number":["C12292\/A11174"]}]},{"name":"Cancer Research U.K.","award":["C1281\/A12014"],"award-info":[{"award-number":["C1281\/A12014"]}]},{"name":"Cancer Research U.K.","award":["C5047\/A8384"],"award-info":[{"award-number":["C5047\/A8384"]}]},{"name":"Cancer Research U.K.","award":["C5047\/A15007"],"award-info":[{"award-number":["C5047\/A15007"]}]},{"name":"Cancer Research U.K.","award":["C5047\/A10692"],"award-info":[{"award-number":["C5047\/A10692"]}]},{"name":"Cancer Research U.K.","award":["C8197\/A16565"],"award-info":[{"award-number":["C8197\/A16565"]}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["CA128978"],"award-info":[{"award-number":["CA128978"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Post-Cancer Genome-Wide Association Study Initiative","award":["1U19 CA148537"],"award-info":[{"award-number":["1U19 CA148537"]}]},{"name":"Post-Cancer Genome-Wide Association Study Initiative","award":["1U19 CA148065"],"award-info":[{"award-number":["1U19 CA148065"]}]},{"name":"Post-Cancer Genome-Wide Association Study Initiative","award":["1U19 CA148112"],"award-info":[{"award-number":["1U19 CA148112"]}]},{"DOI":"10.13039\/100000005","name":"Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-10-1-0341"],"award-info":[{"award-number":["W81XWH-10-1-0341"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CIHR Team in Familial Risks of Breast Cancer"},{"name":"Komen Foundation for the Cure"},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001282","name":"Ovarian Cancer Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001282","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background.<\/jats:title>\n                  <jats:p>A better assessment of individualized prostate cancer (PrCa) risk is needed to improve screening. The use of the prostate-specific antigen (PSA) level for screening in the general population has limitations and is not currently advocated. Approximately 100 common single nucleotide polymorphisms (SNPs) have been identified that are associated with the risk of developing PrCa. The PROFILE pilot study explored the feasibility of using SNP profiling in men with a family history (FH) of PrCa to investigate the probability of detecting PrCa at prostate biopsy (PB). The primary aim of this pilot study was to determine the safety and feasibility of PrCa screening using transrectal ultrasound-guided PB with or without diffusion-weighted magnetic resonance imaging (DW-MRI) in men with a FH. A secondary aim was to evaluate the potential use of SNP profiling as a screening tool in this population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and Methods.<\/jats:title>\n                  <jats:p>A total of 100 men aged 40\u201369 years with a FH of PrCa underwent PB, regardless of their baseline PSA level. Polygenic risk scores (PRSs) were calculated for each participant using 71 common PrCa susceptibility alleles. We treated the disease outcome at PB as the outcome variable and evaluated its associations with the PRS, PSA level, and DW-MRI findings using univariate logistic regression.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results.<\/jats:title>\n                  <jats:p>Of the 100 men, 25 were diagnosed with PrCa, of whom 12 (48%) had clinically significant disease. Four adverse events occurred and no deaths. The PSA level and age at study entry were associated with PrCa at PB (p = .00037 and p = .00004, respectively).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion.<\/jats:title>\n                  <jats:p>The results of the present pilot study have demonstrated that PB is a feasible and safe method of PrCa screening in men with a FH, with a high proportion of PrCa identified requiring radical treatment. It is feasible to collect data on PrCa-risk SNPs to evaluate their combined effect as a potential screening tool. A larger prospective study powered to detect statistical associations is in progress.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2015-0336","type":"journal-article","created":{"date-parts":[[2016,5,6]],"date-time":"2016-05-06T00:45:16Z","timestamp":1462495516000},"page":"716-722","source":"Crossref","is-referenced-by-count":27,"title":["The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate Cancer"],"prefix":"10.1093","volume":"21","author":[{"given":"Elena","family":"Castro","sequence":"first","affiliation":[{"name":"Oncogenetics Team, The Institute of Cancer Research, London, United Kingdom"},{"name":"Academic Urology Unit, The Royal Marsden National Health Service Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Mikropoulos","sequence":"additional","affiliation":[{"name":"Oncogenetics Team, The Institute of Cancer Research, London, United Kingdom"},{"name":"Academic Urology Unit, The Royal Marsden National Health Service Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth K.","family":"Bancroft","sequence":"additional","affiliation":[{"name":"Oncogenetics Team, The Institute of Cancer Research, London, United Kingdom"},{"name":"Academic Urology Unit, The Royal Marsden National Health Service Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tokhir","family":"Dadaev","sequence":"additional","affiliation":[{"name":"Oncogenetics Team, The Institute of Cancer Research, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chee","family":"Goh","sequence":"additional","affiliation":[{"name":"Oncogenetics Team, The Institute of Cancer Research, London, United Kingdom"},{"name":"Academic Urology Unit, The Royal Marsden National Health Service Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Taylor","sequence":"additional","affiliation":[{"name":"Oncogenetics Team, The Institute of Cancer Research, London, United Kingdom"},{"name":"Academic Urology Unit, The Royal Marsden National Health Service Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Saunders","sequence":"additional","affiliation":[{"name":"Oncogenetics Team, The Institute of Cancer Research, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Borley","sequence":"additional","affiliation":[{"name":"Academic Urology Unit, The Royal Marsden National Health Service Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Keating","sequence":"additional","affiliation":[{"name":"Oncogenetics Team, The Institute of Cancer Research, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth C.","family":"Page","sequence":"additional","affiliation":[{"name":"Oncogenetics Team, The Institute of Cancer Research, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibel","family":"Saya","sequence":"additional","affiliation":[{"name":"Oncogenetics Team, The Institute of Cancer Research, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Hazell","sequence":"additional","affiliation":[{"name":"Histopathology Department, The Royal Marsden National Health Service Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Livni","sequence":"additional","affiliation":[{"name":"Histopathology Department, The Royal Marsden National Health Service Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandita","family":"deSouza","sequence":"additional","affiliation":[{"name":"Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Neal","sequence":"additional","affiliation":[{"name":"Department of Oncology, Cancer Research UK Cambridge Institute, Cambridge, United Kingdom"},{"name":"Department of Surgery, Cancer Research UK Cambridge Institute, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freddie C.","family":"Hamdy","sequence":"additional","affiliation":[{"name":"Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardeep","family":"Kumar","sequence":"additional","affiliation":[{"name":"Academic Urology Unit, The Royal Marsden National Health Service Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonis C.","family":"Antoniou","sequence":"additional","affiliation":[{"name":"Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsofia","family":"Kote-Jarai","sequence":"additional","affiliation":[{"name":"Oncogenetics Team, The Institute of Cancer Research, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The PROFILE Study Steering Committee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalind A.","family":"Eeles","sequence":"additional","affiliation":[{"name":"Oncogenetics Team, The Institute of Cancer Research, London, United Kingdom"},{"name":"Academic Urology Unit, The Royal Marsden National Health Service Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,5,5]]},"reference":[{"key":"2021122401031271400_B1","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1200\/JCO.2011.40.4327","article-title":"Prostate cancer screening: Facts, statistics, and interpretation in response to the US Preventive Services Task Force Review","volume":"30","author":"Carlsson","year":"2012","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2021122401031271400_B2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1464-410X.2012.011428.x","article-title":"Landmarks in prostate cancer screening","volume":"110","author":"Schr\u00f6der","year":"2012","journal-title":"BJU Int"},{"key":"2021122401031271400_B3","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.urolonc.2012.09.009","article-title":"PSA screening and prostate cancer risk reduction","volume":"30","author":"Andriole","year":"2012","journal-title":"Urol Oncol"},{"key":"2021122401031271400_B4","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1200\/JCO.2012.43.3441","article-title":"Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion","volume":"30","author":"Basch","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122401031271400_B5","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/nrurol.2013.266","article-title":"The genetic epidemiology of prostate cancer and its clinical implications","volume":"11","author":"Eeles","year":"2014","journal-title":"Nat Rev Urol"},{"key":"2021122401031271400_B6","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1002\/pros.21002","article-title":"Estimation of absolute risk for prostate cancer using genetic markers and family history","volume":"69","author":"Xu","year":"2009","journal-title":"Prostate"},{"key":"2021122401031271400_B7","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.eururo.2012.05.006","article-title":"Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: Findings from the REDUCE trial","volume":"62","author":"Kader","year":"2012","journal-title":"Eur Urol"},{"key":"2021122401031271400_B8","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejro.2014.08.002","article-title":"Diffusion-weighted MRI for detecting prostate tumour in men at increased genetic risk","volume":"1","author":"deSouza","year":"2014","journal-title":"Eur J Radiol Open"},{"key":"2021122401031271400_B9","volume-title":"Prostate Cancer: Diagnosis and Treatment","author":"National Institute for Health and Care Excellence","year":"2008"},{"key":"2021122401031271400_B10","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/ng.2560","article-title":"Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array","volume":"45","author":"Eeles","year":"2013","journal-title":"Nat Genet"},{"key":"2021122401031271400_B11","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/ng.2592","article-title":"iCOGS collection provides a collaborative model. Foreword","volume":"45","author":"Bahcall","year":"2013","journal-title":"Nat Genet"},{"key":"2021122401031271400_B12","volume-title":"R: A language and environment for statistical computing","author":"R Core Team","year":"2014"},{"key":"2021122401031271400_B13","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1056\/NEJMoa031918","article-title":"Prevalence of prostate cancer among men with a prostate-specific antigen level &lt; or =4.0 ng per milliliter","volume":"350","author":"Thompson","year":"2004","journal-title":"N Engl J Med"},{"key":"2021122401031271400_B14","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/j.1464-410X.2012.11648.x","article-title":"Clinical implications of family history of prostate cancer and genetic risk single nucleotide polymorphism (SNP) profiles in an active surveillance cohort","volume":"112","author":"Goh","year":"2013","journal-title":"BJU Int"},{"key":"2021122401031271400_B15","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.juro.2012.10.005","article-title":"Is repeat prostate biopsy associated with a greater risk of hospitalization? Data from SEER-Medicare","volume":"189","author":"Loeb","year":"2013","journal-title":"J Urol"},{"key":"2021122401031271400_B16","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1200\/JCO.2012.45.4801","article-title":"Psychological impact of prostate biopsy: Physical symptoms, anxiety, and depression","volume":"31","author":"Wade","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122401031271400_B17","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/pros.20887","article-title":"Clinical utility of five genetic variants for predicting prostate cancer risk and mortality","volume":"69","author":"Salinas","year":"2009","journal-title":"Prostate"},{"key":"2021122401031271400_B18","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1158\/1078-0432.CCR-08-1593","article-title":"Utility of incorporating genetic variants for the early detection of prostate cancer","volume":"15","author":"Nam","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2021122401031271400_B19","doi-asserted-by":"crossref","first-page":"e46454","DOI":"10.1371\/journal.pone.0046454","article-title":"Reproducibility, performance, and clinical utility of a genetic risk prediction model for prostate cancer in Japanese","volume":"7","author":"Akamatsu","year":"2012","journal-title":"PLoS One"},{"key":"2021122401031271400_B20","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.eururo.2011.10.047","article-title":"Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men","volume":"61","author":"Klein","year":"2012","journal-title":"Eur Urol"},{"key":"2021122401031271400_B21","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.eururo.2013.07.005","article-title":"A genetic score can identify men at high risk for prostate cancer among men with prostate-specific antigen of 1-3 ng\/ml","volume":"65","author":"Nordstr\u00f6m","year":"2014","journal-title":"Eur Urol"},{"key":"2021122401031271400_B22","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/jnci\/dji128","article-title":"Cancer risk prediction models: A workshop on development, evaluation, and application","volume":"97","author":"Freedman","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"2021122401031271400_B23","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1158\/1078-0432.CCR-08-1743","article-title":"Genetic variants and family history predict prostate cancer similar to prostate-specific antigen","volume":"15","author":"Zheng","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2021122401031271400_B24","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.canep.2010.07.012","article-title":"Validation of a modelling approach for estimating the likely effectiveness of cancer screening using cancer data on prevalence screening and incidence","volume":"35","author":"Pashayan","year":"2011","journal-title":"Cancer Epidemiol"},{"key":"2021122401031271400_B25","first-page":"549","article-title":"A risk prediction algorithm based on family history and common genetic variants: Application to prostate cancer with potential clinical impact","volume":"35","author":"Macinnis","year":"2011","journal-title":"Genet Epidemiol"},{"key":"2021122401031271400_B26","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00439-013-1384-2","article-title":"Association analysis of 9,560 prostate cancer cases from the International Consortium of Prostate Cancer Genetics confirms the role of reported prostate cancer associated SNPs for familial disease","volume":"133","author":"Teerlink","year":"2014","journal-title":"Hum Genet"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2015-0336","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2015-0336","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/21\/6\/716\/41875162\/oncolo_21_6_716.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/21\/6\/716\/41875162\/oncolo_21_6_716.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T06:39:20Z","timestamp":1640327960000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/21\/6\/716\/6401420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,5]]},"references-count":26,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2016,5,5]]},"published-print":{"date-parts":[[2016,6,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2015-0336","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,6,1]]},"published":{"date-parts":[[2016,5,5]]}}}